Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 106.1 HKD 1.34% Market Closed
Market Cap: 144.6B HKD
Have any thoughts about
Beigene Ltd?
Write Note

Beigene Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beigene Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Current Liabilities
ÂĄ4.1B
CAGR 3-Years
23%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Total Current Liabilities
ÂĄ1.4B
CAGR 3-Years
100%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
71%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Liabilities
ÂĄ297.7m
CAGR 3-Years
49%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

Beigene Ltd
Glance View

Market Cap
146.3B HKD
Industry
Biotechnology

BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.

Intrinsic Value
177.75 HKD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Beigene Ltd's Total Current Liabilities?
Total Current Liabilities
12.8B CNY

Based on the financial report for Dec 31, 2023, Beigene Ltd's Total Current Liabilities amounts to 12.8B CNY.

What is Beigene Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
50%

Over the last year, the Total Current Liabilities growth was 25%. The average annual Total Current Liabilities growth rates for Beigene Ltd have been 22% over the past three years , 50% over the past five years .

Back to Top